163 results on '"Brasó-Maristany F"'
Search Results
2. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)
3. Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer
4. Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis
5. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer
6. Identification of cell surface targets for CAR-T cell therapies and antibody–drug conjugates in breast cancer
7. 124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial
8. PD-0827 Radiotherapy upregulates the expression of selected immune genes in early-stage breast cancer
9. 3MO HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): A correlative analysis from SOLTI-TOT-HER3 trial
10. 55P Clinicopathological and molecular changes induced by neoadjuvant therapy (NAT) in hormone receptor-positive (HR+)/HER2-low vs HER2 0 breast cancer (BC)
11. 7P Independent validation of HER2DX ERBB2 mRNA score to predict HER2-positive (HER2+), HER2-low and HER2-0 status in breast cancer
12. 102P HER2DX risk-score in early-stage HER2-positive (HER2+) breast cancer: A correlative analysis of 757 patients from the Sweden Cancerome Analysis Network - Breast (SCAN-B) dataset
13. 12P HER2DX in HER2-positive (HER2+) inflammatory breast cancer (IBC): A correlative analysis from a phase II clinical trial
14. 11P Independent validation of the HER2DX assay in HER2-positive (HER2+) breast cancer (BC) treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): A correlative analysis from the BiOnHER study
15. 5P HER2DX risk-score in HER2-positive (HER2+) breast cancer following neoadjuvant and adjuvant anti-HER2-based treatment: An updated survival analysis
16. 8P First decision impact study of HER2DX in patients (pts) with HER2-positive (HER2+) early breast cancer
17. 126MO HER2DX and pathological complete response in HER2-positive breast cancer: A combined analysis of 4 neoadjuvant studies
18. 10P HER2 loss and PAM50 dynamics after neoadjuvant therapy (NAT) in HER2-positive (HER2+) early breast cancer (BC)
19. 6P Combined analysis of the HER2DX genomic tool in adjuvant APT and ATEMPT trials
20. 13P Analytical validation of HER2DX test for early-hER2+ breast cancer
21. 237P HER2DX genomic assay in advanced HER2-positive (HER2+) breast cancer treated with T-DM1
22. 153P HER2DX risk-score in the context of the PREDICT online-tool: A correlative analysis of the Short-HER clinical trial in early-stage HER2-positive (HER2+) breast cancer (BC)
23. 263P Clinical outcomes in patients with germline pathogenic variants in homologous recombination repair (HRR) genes treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET)
24. PD-0487 Radiotherapy-induced gene expression changes in breast cancer cell lines
25. 3MO Association of the research-based HER2DX signatures with survival in early-stage triple-negative breast cancer (eTNBC)
26. 10P Survival according to early ctDNA dynamics in advanced breast cancer (ABC) treated with endocrine therapy (ET) and a CDK4/6 inhibitor (CDK4/6i)
27. 25P Research-based HER2DX in patients with early-stage HER2-positive (HER2+) breast cancer treated in the N9831 phase III clinical trial
28. 275P Clinical and molecular impact of neoadjuvant chemotherapy (NACT) or endocrine therapy (NET) on hormone receptor positive (HR+)/HER2-negative (-) breast cancer (BC)
29. 2246P Tumor-infiltrating lymphocites and gene expression across multiple cancer-types: A translational analysis from the SOLTI-1904-ACROPOLI study
30. 2239P Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types
31. 150P Validation of a genomic assay in early-stage HER2+ breast cancer (BC) treated with trastuzumab and pertuzumab (HP): A correlative analysis from PHERGain phase II trial
32. 149P Assessing the effect of single dose trastuzumab and pertuzumab (HP) on biological changes and pathological complete response (pCR) in ERBB2+ Breast Cancer: Results from the neoadjuvant BionHER study
33. 109P Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)
34. 23P CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): A retrospective analysis of real-world data
35. 16P Understanding the biologic determinants of ribociclib efficacy in breast cancer
36. 1481P Expression of ERBB2 and PD1 mRNA in advanced gastric cancer
37. 23P Clinical, pathological and gene expression features of HER2-low breast cancer
38. 12P Gene expression profiling in early breast cancer treated with neoadjuvant ribociclib plus letrozole (R+L) versus chemotherapy (CT): A correlative analysis of the SOLTI-1402/CORALLEEN phase II trial
39. 5P Circulating tumour DNA (ctDNA) dynamics using a standardized multi-gene panel in advanced breast cancer patients (pts) treated with CDK4/6 inhibitors (CDK4/6i)
40. 168P Development of a combined clinical model to predict progression-free survival (PFS) in advanced breast cancer (ABC) treated with CDK4/6 inhibitors (CDK4/6i)
41. ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): A retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials
42. 147P Breast cancer in women with germline pathogenic variants: Frequency, clinical behavior, and outcomes of a consecutive series of patients from Spain
43. ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC)
44. Abstract PD9-04: FGFR4 as a key regulator of HER2E subtype in the primary and metastatic setting
45. Abstract P6-17-07: Gene signatures and subtype changes during HER2 dual blockade in PAM50 HER2-enriched HER2-positive breast cancer
46. 119P - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): A retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials
47. 10P - PIM1 kinase promotes cell migration via SHP2 in triple-negative breast cancer
48. 20P ERBB2 mRNA as predictor of response to anti-HER2 antibody-drug conjugates (ADC) in breast cancer (BC).
49. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease
50. 391P Real-world activity of sacituzumab govitecan for metastatic breast cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.